Target intelligence / Profile preview

Off-target messenger RNAs with partial complementarity to siRNA seed region (siRNA off-targets)

Target
siRNA off-targets
Molecular classification
Messenger RNA, Nucleic acid
01

Overview

Off-target messenger RNAs with partial complementarity to the siRNA seed region refer to a broad set of unintended transcripts that are downregulated by small interfering RNA (siRNA) drugs. This effect is primarily mediated by the seed region of the siRNA guide strand (nucleotides 2 through 8), which can bind to the 3' untranslated regions (UTRs) of mRNAs with only partial complementarity (Jackson et al., 2003). This interaction mimics the endogenous microRNA (miRNA) pathway, leading to the recruitment of the RNA-induced silencing complex (RISC) and subsequent translational repression or mRNA decay of the unintended transcript (Birmingham et al., 2006). Because the seed sequence is short, a single siRNA can potentially interact with hundreds of off-target mRNAs, leading to unintended biological effects or toxicity (Janas et al., 2018). To mitigate these risks, therapeutic siRNAs are often engineered with chemical modifications, such as 2'-O-methyl (2'-OMe) substitutions at position 2 of the guide strand, to destabilize off-target binding without compromising on-target activity (Setten et al., 2019). Understanding and predicting these off-target profiles is a critical component of the safety assessment for RNAi-based therapeutics like Patisiran and Inclisiran.

Other names
Seed-mediated off-targetsmiRNA-like off-target effectssiRNA off-target effectsUnintended mRNA targets
02

Mechanism of action

siRNAs loaded into the RNA-induced silencing complex (RISC) bind to unintended mRNAs via partial complementarity of the seed region (nucleotides 2-8), leading to miRNA-like translational repression or mRNA decay (Jackson et al., 2003; Birmingham et al., 2006).

03

Biological functions

Gene expression regulationRNA interference
04

Disease associations

ToxicityUnintended gene silencing
05

Safety considerations

HepatotoxicityUnintended phenotypic changesOff-target gene knockdownSaturation of the RNAi machinery
06

Interacting drugs

Patisiran

5 more in the full profile.

07

Biomarkers

RNA-seq transcriptome profilingMicroarray analysisDual-luciferase reporter assays

Beyond the preview

Go deeper on Off-target messenger RNAs with partial complementarity to siRNA seed region (siRNA off-targets).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Off-target messenger RNAs with partial complementarity to siRNA seed region (siRNA off-targets).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call